Landiolol Dosage

Medically reviewed by Drugs.com. Last updated on May 6, 2025.

Usual Adult Dose for Supraventricular Tachycardia

Normal Cardiac Function:

• Starting dose: 9 mcg/kg/min IV
• Titration interval: 10 minutes
• Titration step: 9 mcg/kg/min IV
• Maximum dose: 36 mcg/kg/min IV

Impaired Cardiac Function:

• Starting dose: 1 mcg/kg/min IV
• Titration interval: 15 min
• Titration step: 1 mcg/kg/min IV
• Maximum dose: 36 mcg/kg/min IV

Comments:

• This drug is administered as a continuous IV infusion, titrating as needed for heart rate control.
• Limited data are available beyond 24 hours of use.
• The infusion rate can be calculated as: Infusion rate (mL/hour) = target dose (mcg/kg/min) multiplied by body weight (kg) divided by 93

Use: For the short-term reduction of ventricular rate in patients with supraventricular tachycardia (including atrial fibrillation and atrial flutter)

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Mild liver dysfunction (Child-Pugh A): Dose titration should be more conservative.
Moderate or severe liver dysfunction (Child-Pugh B or C): Not recommended

Comments:

• The effect of moderate or severe liver dysfunction on drug pharmacokinetics is unknown.

Dose Adjustments

Transitioning to Alternative Medications:

• When transitioning from this drug, consider the pharmacodynamics of the medication the patient is being transitioned to and monitor clinical response; if switched to an oral beta-blocker, the dosage of this drug can be reduced as follows:
• Ten minutes after administering the oral beta-blocker, reduce the infusion rate of this drug by 50%.
• If satisfactory control is maintained for at least 1 hour, discontinue this drug.

Precautions

CONTRAINDICATIONS:

• Severe sinus bradycardia, sick sinus syndrome, heart block greater than first degree
• Decompensated heart failure
• Cardiogenic shock (may precipitate further cardiovascular collapse and cause cardiac arrest)
• Pulmonary hypertension (may precipitate cardiorespiratory decompensation)
• Hypersensitivity reactions (including anaphylaxis) to the active component or any of the ingredients

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• Administer as a continuous IV infusion in a monitored setting.

Storage requirements:

• Unreconstituted lyophilized powder: Store at 20C to 25C (68F to 77F); excursions permitted to 15C to 30C (59F to 86F).
• Reconstituted solution: If not used immediately:
• If 0.9% Sodium Chloride Injection, USP was used as the diluent: Use within 4 hours at room temperature (25C [77F]).
• If 5% Dextrose Injection, USP was used as the diluent: Use within 48 hours at room temperature (25C [77F]).

Reconstitution/preparation techniques:

• Reconstitution is necessary before administration.
• The manufacturer product information should be consulted.

IV compatibility:

• Compatible: 0.9% Sodium Chloride Injection, USP; 5% Dextrose Injection, USP

General:

• Landiolol 9 mg/kg/min is equivalent to landiolol hydrochloride 9.6 mcg/kg/min.
• After reconstitution, the product contains landiolol 280 mg/50 mL (5.6 mg/mL).

Monitoring:

• Cardiovascular: Blood pressure; heart rate and rhythm (during therapy); for signs of myocardial ischemia (when discontinuing this drug)
• Endocrine: For signs of thyrotoxicosis in patients with hyperthyroidism (when withdrawing this drug)
• General: For clinical response (during transition to alternative medications)
• Metabolic: Serum electrolytes (during therapy); for signs/symptoms of hypoglycemia (during therapy)

See also:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer